211 related articles for article (PubMed ID: 35127252)
1. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.
Hagiwara M; Fushimi A; Bhattacharya A; Yamashita N; Morimoto Y; Oya M; Withers HG; Hu Q; Liu T; Liu S; Wong KK; Long MD; Kufe D
Oncoimmunology; 2022; 11(1):2029298. PubMed ID: 35127252
[TBL] [Abstract][Full Text] [Related]
2. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
Yamashita N; Morimoto Y; Fushimi A; Ahmad R; Bhattacharya A; Daimon T; Haratake N; Inoue Y; Ishikawa S; Yamamoto M; Hata T; Akiyoshi S; Hu Q; Liu T; Withers H; Liu S; Shapiro GI; Yoshizumi T; Long MD; Kufe D
Mol Cancer Res; 2023 Mar; 21(3):274-289. PubMed ID: 36445328
[TBL] [Abstract][Full Text] [Related]
3. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
4. MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.
Bhattacharya A; Fushimi A; Yamashita N; Hagiwara M; Morimoto Y; Rajabi H; Long MD; Abdulla M; Ahmad R; Street K; Liu S; Liu T; Kufe D
Mol Cancer Res; 2022 Apr; 20(4):556-567. PubMed ID: 35022313
[TBL] [Abstract][Full Text] [Related]
5. MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells.
Hagiwara M; Yasumizu Y; Yamashita N; Rajabi H; Fushimi A; Long MD; Li W; Bhattacharya A; Ahmad R; Oya M; Liu S; Kufe D
Cancer Res; 2021 Feb; 81(4):1111-1122. PubMed ID: 33323379
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
Hagiwara M; Fushimi A; Yamashita N; Bhattacharya A; Rajabi H; Long MD; Yasumizu Y; Oya M; Liu S; Kufe D
Oncogene; 2021 Jul; 40(30):4930-4940. PubMed ID: 34163028
[TBL] [Abstract][Full Text] [Related]
7. Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer.
Kufe D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835130
[TBL] [Abstract][Full Text] [Related]
8. MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.
Hata T; Rajabi H; Takahashi H; Yasumizu Y; Li W; Jin C; Long MD; Hu Q; Liu S; Fushimi A; Yamashita N; Kui L; Hong D; Yamamoto M; Miyo M; Hiraki M; Maeda T; Suzuki Y; Samur MK; Kufe D
Cancer Res; 2019 Nov; 79(22):5711-5722. PubMed ID: 31519689
[TBL] [Abstract][Full Text] [Related]
9. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
10. Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells.
Kufe DW
J Cancer Metastasis Treat; 2022; 8():. PubMed ID: 35539431
[TBL] [Abstract][Full Text] [Related]
11. Casein Kinase 1α Mediates the Degradation of Receptors for Type I and Type II Interferons Caused by Hemagglutinin of Influenza A Virus.
Xia C; Wolf JJ; Vijayan M; Studstill CJ; Ma W; Hahm B
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343571
[TBL] [Abstract][Full Text] [Related]
12. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma upregulates MUC1 expression in haematopoietic and epithelial cancer cell lines, an effect associated with MUC1 mRNA induction.
Reddy PK; Gold DV; Cardillo TM; Goldenberg DM; Li H; Burton JD
Eur J Cancer; 2003 Feb; 39(3):397-404. PubMed ID: 12565994
[TBL] [Abstract][Full Text] [Related]
14. IDENTIFICATION OF MUC1-C AS A TARGET FOR SUPPRESSING PROGRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS.
Nakashoji A; Haratake N; Bhattacharya A; Mao W; Xu K; Wang K; Daimon T; Ozawa H; Shigeta K; Fushimi A; Yamashita N; Morimoto Y; Shimokawa M; Saito S; Egloff AM; Uppaluri R; Long MD; Kufe D
Cancer Res Commun; 2024 Apr; ():. PubMed ID: 38619287
[TBL] [Abstract][Full Text] [Related]
15. Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer.
Yamashita N; Fushimi A; Morimoto Y; Bhattacharya A; Hagiwara M; Yamamoto M; Hata T; Shapiro GI; Long MD; Liu S; Kufe D
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681561
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment.
Xiang S; Zou P; Wu J; Zheng F; Tang Q; Zhou J; Hann SS
Cell Physiol Biochem; 2018; 47(2):759-773. PubMed ID: 29807357
[TBL] [Abstract][Full Text] [Related]
17. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
[TBL] [Abstract][Full Text] [Related]
18. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vesicles from neural stem cells transfer IFN-γ via Ifngr1 to activate Stat1 signaling in target cells.
Cossetti C; Iraci N; Mercer TR; Leonardi T; Alpi E; Drago D; Alfaro-Cervello C; Saini HK; Davis MP; Schaeffer J; Vega B; Stefanini M; Zhao C; Muller W; Garcia-Verdugo JM; Mathivanan S; Bachi A; Enright AJ; Mattick JS; Pluchino S
Mol Cell; 2014 Oct; 56(2):193-204. PubMed ID: 25242146
[TBL] [Abstract][Full Text] [Related]
20. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.
Khodarev N; Ahmad R; Rajabi H; Pitroda S; Kufe T; McClary C; Joshi MD; MacDermed D; Weichselbaum R; Kufe D
Oncogene; 2010 Feb; 29(6):920-9. PubMed ID: 19915608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
